A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy.

Shen YT, Lynch JJ, Hargreaves RJ, Gould RJ

The Journal of pharmacology and experimental therapeutics15 May 2003Cited by 12 (Europe PMC)

PMID12750438DOI10.1124/jpet.103.050997PepBankPUB-12750438

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dogs, myocardial blood flow did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion.
In plain wordsIn dogs, heart blood flow did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion.
Peptide
GHRP-6
Outcome
No significant changeMyocardial blood flow
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Source sentences
Summary
There were no differences in myocardial blood flow, hemodynamics, or arrhythmic beats among all groups during CAO and reperfusion periods.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043808
02AnimalAnimal study (in vivo)Efficacy outcome
In dogs, hemodynamics did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion.
In plain wordsIn dogs, blood circulation measures did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion.
Peptide
GHRP-6
Outcome
No significant changeHemodynamics
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Source sentences
Summary
There were no differences in myocardial blood flow, hemodynamics, or arrhythmic beats among all groups during CAO and reperfusion periods.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043809
03AnimalAnimal study (in vivo)Safety outcome
In dogs, arrhythmic beats did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion.
In plain wordsIn dogs, irregular heartbeats did not differ between GHRP‑6, GH, and vehicle during occlusion and reperfusion.
Peptide
GHRP-6
Outcome
No significant changeArrhythmic beats
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Source sentences
Summary
There were no differences in myocardial blood flow, hemodynamics, or arrhythmic beats among all groups during CAO and reperfusion periods.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043810
04AnimalAnimal study (in vivo)Efficacy outcome
In dogs, GHRP‑6 increased nonischemic wall thickening more than vehicle after reperfusion.
In plain wordsIn dogs, GHRP‑6 increased nonischemic heart wall thickening more than vehicle after reperfusion.
Peptide
GHRP-6
Outcome
IncreaseNonischemic wall thickening versus vehicle
Study
dogsn = 19
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Source sentences
Summary
WT in nonischemic regions, however, was enhanced in the GHRP-6 group compared with the GH and vehicle groups, e.g., increase of WT after 1 h of reperfusion was greater (p <0.05) in the GHRP-6 (+53 +/- 8%) than in the GH (+14 +/- 12%) or (+14 +/- 6%).
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043807
05AnimalAnimal study (in vivo)Safety outcome
In dogs, no GHRP‑6-treated animals died during coronary occlusion, compared with 55% survival with vehicle.
In plain wordsIn dogs, none died with GHRP‑6 during coronary occlusion, compared with 55% survival with vehicle.
Peptide
GHRP-6
Outcome
DecreaseDeath during occlusion versus vehicle
Study
dogsn = 19
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
Vehicle
Outcome group
Mortality · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Source sentences
Summary
Strikingly, no dogs in the GHRP-6 group died during CAO, whereas the survival rates for GH and vehicle groups were 57 and 55%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043812
06AnimalAnimal study (in vivo)Efficacy outcome
In dogs, GHRP‑6 increased nonischemic wall thickening more than GH after reperfusion.
In plain wordsIn dogs, GHRP‑6 increased nonischemic heart wall thickening more than GH after reperfusion.
Peptide
GHRP-6
Outcome
IncreaseNonischemic wall thickening versus GH
Study
dogsn = 15
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH
Outcome group
Heart function · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Measurements
Wall thickening increase
53%
GHRP-6
Wall thickening increase
14%
GH
Source sentences
Summary
WT in nonischemic regions, however, was enhanced in the GHRP-6 group compared with the GH and vehicle groups, e.g., increase of WT after 1 h of reperfusion was greater (p <0.05) in the GHRP-6 (+53 +/- 8%) than in the GH (+14 +/- 12%) or (+14 +/- 6%).
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043806
07AnimalAnimal study (in vivo)Safety outcome
In dogs, no GHRP‑6-treated animals died during coronary occlusion, compared with 57% survival with GH.
In plain wordsIn dogs, none died with GHRP‑6 during coronary occlusion, compared with 57% survival with GH.
Peptide
GHRP-6
Outcome
DecreaseDeath during occlusion versus GH
Study
dogsn = 15
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH
Outcome group
Mortality · Cardiovascular
Studied dose
0.2 mg/kg/day · subcutaneousAs given in this study (dogs).
Source sentences
Summary
Strikingly, no dogs in the GHRP-6 group died during CAO, whereas the survival rates for GH and vehicle groups were 57 and 55%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
Report a problemFND-1275043811

Studies that did not test the peptide alone5

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

08AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In dogs, LV pressure fell similarly in all pacing groups, including GHRP‑6, GH, and vehicle.
In plain wordsIn dogs, heart pressure fell similarly in all pacing groups, including GHRP‑6 and vehicle.
Peptide
GHRP-6
Outcome
No significant changeLV pressure
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Two weeks of pacing was associated with similar decreases in LV pressure, rate of change of LV pressure, systolic wall thickening (WT), and an increase in left atrial pressure in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1275043801
09AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In dogs, the rate of LV pressure change fell similarly in all pacing groups, including GHRP‑6 and vehicle.
In plain wordsIn dogs, the rate of heart pressure change fell similarly in all pacing groups, including GHRP‑6 and vehicle.
Peptide
GHRP-6
Outcome
No significant changeRate of change of LV pressure
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Two weeks of pacing was associated with similar decreases in LV pressure, rate of change of LV pressure, systolic wall thickening (WT), and an increase in left atrial pressure in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1275043802
10AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In dogs, systolic wall thickening fell similarly in all pacing groups, including GHRP‑6 and vehicle.
In plain wordsIn dogs, heart wall thickening fell similarly in all pacing groups, including GHRP‑6 and vehicle.
Peptide
GHRP-6
Outcome
No significant changeSystolic wall thickening during pacing
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Two weeks of pacing was associated with similar decreases in LV pressure, rate of change of LV pressure, systolic wall thickening (WT), and an increase in left atrial pressure in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1275043803
11AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In dogs, left atrial pressure rose in all pacing groups, including GHRP‑6 and vehicle.
In plain wordsIn dogs, left atrial pressure rose in all pacing groups, including GHRP‑6 and vehicle.
Peptide
GHRP-6
Outcome
No significant changeLeft atrial pressure
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Two weeks of pacing was associated with similar decreases in LV pressure, rate of change of LV pressure, systolic wall thickening (WT), and an increase in left atrial pressure in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1275043804
12AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In dogs, coronary occlusion caused similar ischemic wall thickening loss without reperfusion recovery in all groups, including GHRP‑6.
In plain wordsIn dogs, ischemic wall thickening fell similarly and did not recover in all groups, including GHRP‑6 and vehicle.
Peptide
GHRP-6
Outcome
No significant changeIschemic wall thickening
Study
dogsn = 26
Pacing-induced dilated cardiomyopathy with coronary artery occlusion
Comparator
GH and vehicle
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Coronary artery occlusion (CAO) resulted in a similar loss of WT in ischemic regions, which did not recover during reperfusion period in all groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Beginning 1 week after ventricular pacing (240 beats/min) was initiated, dogs were treated (s.c.) with GH releasing peptide-6 (GHRP-6, n = 8, 0.2 mg/kg/day), GH (n = 7, 0.06 mg/kg/day), or vehicle (n = 11).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1275043805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.